Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

Benzinga · 1d ago
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.